Tag Archives: parenteral products

Removing Gaps in Data Integrity

Between January 2015 and May 2016 there was a total of 28 warning letters issued to pharmaceutical manufacturers. 21 of those letters were centered around issues involving data integrity.  If data is mutilated and changed, it does not promise that a product is safe, data integrity is extremely important to follow.  It is used to…
Read more

Testing Container Closures

During the manufacturing process of injectable drugs, all pieces and parts need to go through a visual inspection process.  The container, closure, product and final product all need to have individual inspections.  Container closure integrity is extremely important, especially when involved with parenteral drugs.  Parenteral drugs have the highest risk packaging application concern for closure…
Read more

Pfizer’s Newest Vaccine Plant Has History of Mold Issues and Recalls

On Wednesday, March 10th 2021, WebMD posted an article with information on the newest vaccine plant the FDA are allowing to produce COVID-19 vaccines.  This plant is owned by Pfizer, located in Kansas and is now booked to produce the most urgently needed drug product.  Although, there is one main concern; there is a known…
Read more

Essentially Free:  How A Definition Tamed The Visible Particulate Matter Debate

In an article written by Louis Garguilo, Chief Editor for Outsourced Pharma, it talks about defining the term “essentially free” of visible particulate matter.  In 2005, it has become a big concern with the number of injectable drug product batches being rejected or recalled because of particulate matter being present. In 2014, recalls in injectable…
Read more